Inpatient management of iron deficiency anemia in pediatric patients with inflammatory bowel disease: A single center experience

Table 3 Comparison of intravenous iron types (n = 57)

		Iron therapy			P value	Difference (95%CI)
		Venofer (n = 19)	Injectafer (n = 16)	INFeD (n = 22)		Injectafer-Venofer	INFeD-Venofer	Injectafer-INFeD
Hb (g/dL)	Admission	9.4 ± 0.3	9.5 ± 0.2	9.4 ± 0.2
(n = 57)	Follow-up	10.5 ± 0.3	11.9 ± 0.2	11.7 ± 0.2
	Change	1.0 ± 0.3a	2.4 ± 0.3b	2.2 ± 0.3b	0.009	1.3 (0.2, 2.5)a	1.2 (0.1, 2.3)a	0.1 (-1.0, 1.2)
Ferritin (μg/dL)	Admission	117 ± 36	82 ± 33	73 ± 36
(n = 43)	Follow-up	153 ± 39	183 ± 45	206 ± 42
	Change	37 ± 43	101 ± 57	133 ± 44	0.3	64 (-118, 247)	96 (-61, 254)	-32 (-215, 151)
Iron (μg/dL)	Admission	19.2 ± 6.5	23.0 ± 5.8	25.3 ± 6.5
(n = 43)	Follow-up	27.5 ± 7.0	80.7 ± 8.0	67.1 ± 7.4
	Change	8.3 ± 7.1a	57.7 ± 9.7b	41.7 ± 7.3b	0.0006	49.4 (18.5, 80.2)c	33.5 (7.4, 59.6)b	15.9 (-15.0, 46.8)

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

Effects with different superscripts are statistically significant at P < 0.05, mean ± standard error at admission, follow-up encounter, and change over time are shown. Results are from a repeated measures linear model adjusted for baseline outcome, age at admission, sex, diagnosis, baseline iron dose, and the number of days between admission and follow-up labs. The 95% confidence interval is adjusted for multiple comparisons using the Bonferroni step-down procedure. Hb: Hemoglobin; CI: Confidence interval; INFeD: Low-molecular-weight iron dextran.